Venus Medtech HangZhou Inc (Venus MedTech) is a medical device company that develops and commercializes transcatheter heart valve products for structural heart diseases. The company's products include Venus-PowerX, Venus-Vitae, AR Valve, VenusA-Valve, VenusA-Plus, VenusA-Pro, VenusP-Valve, VenusA series, among others. Venus-PowerX, VenusA series, Venus-Vitae, AR Valveare are for the treatment of patients with aortic valve stenosis. Its pulmonary valve treats severe pulmonary regurgitation with or without RVOT stenosis, mitral valve for mitral and tricuspid valve diseases and Liwen RF and Echomplish Platform targets structural heart disease. Venus MedTech is headquartered in Hangzhou, Zhejiang, China.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Venus Medtech Hangzhou Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Venus Medtech Hangzhou Inc Company Overview
- Venus Medtech Hangzhou Inc Company Snapshot
- Venus Medtech Hangzhou Inc Pipeline Products and Ongoing Clinical Trials Overview
- Venus Medtech Hangzhou Inc - Pipeline Analysis Overview
- Venus Medtech Hangzhou Inc - Key Facts
- Venus Medtech Hangzhou Inc - Major Products and Services
- Venus Medtech Hangzhou Inc Pipeline Products by Development Stage
- Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status
- Venus Medtech Hangzhou Inc Pipeline Products Overview
- AR Valve
- AR Valve Product Overview
- Cardiovalve
- Cardiovalve Product Overview
- Cardiovalve Transcatheter Tricuspid Valve System
- Cardiovalve Transcatheter Tricuspid Valve System Product Overview
- Cardiovalve Transcatheter Tricuspid Valve System Clinical Trial
- Cardiovalve Transfemoral Mitral Valve System
- Cardiovalve Transfemoral Mitral Valve System Product Overview
- Cardiovalve Transfemoral Mitral Valve System Clinical Trial
- Echomplish Device
- Echomplish Device Product Overview
- Lim Transseptal System
- Lim Transseptal System Product Overview
- Limbus
- Limbus Product Overview
- Liwen RF Ablation System
- Liwen RF Ablation System Product Overview
- Liwen RF Ablation System Clinical Trial
- Small Incision Surgical Valve
- Small Incision Surgical Valve Product Overview
- Transapical Trinity Aortic Valve Implantation System
- Transapical Trinity Aortic Valve Implantation System Product Overview
- Transcatheter Tricuspid Valve Replacement Device
- Transcatheter Tricuspid Valve Replacement Device Product Overview
- Transfemoral Trinity Aortic Valve Implantation System
- Transfemoral Trinity Aortic Valve Implantation System Product Overview
- Tresillo System
- Tresillo System Product Overview
- TriGUARD3 Cerebral Embolic Protection Device
- TriGUARD3 Cerebral Embolic Protection Device Product Overview
- Tumbao EndoVascular Aortic Repair System
- Tumbao EndoVascular Aortic Repair System Product Overview
- Venus PowerX Valve
- Venus PowerX Valve Product Overview
- Venus PowerX Valve Clinical Trial
- Venus Vitae Valve
- Venus Vitae Valve Product Overview
- Venus Vitae Valve Clinical Trial
- Venus-Neo
- Venus-Neo Product Overview
- Venus-Neo Clinical Trial
- VenusP-Valve
- VenusP-Valve Product Overview
- VenusP-Valve Clinical Trial
- Venus Medtech Hangzhou Inc - Key Competitors
- Venus Medtech Hangzhou Inc - Key Employees
- Venus Medtech Hangzhou Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Recent Developments
- Venus Medtech Hangzhou Inc, Recent Developments
- Mar 28, 2025: Venus Medtech Announces Annual Results for Year Ended December 31, 2024
- Sep 05, 2024: Two National Medical Device Standards Released with Venus Medtech’s Contribution
- Sep 05, 2024: Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
- May 09, 2024: Governor Wang Hao of Zhejiang Province Visits Venus Medtech to Inspect Large-Scale Equipment Renewal and Consumer Goods Trade-Ins
- Apr 23, 2024: Venusa-Plus Four-Year Clinical Data Released: Comparable or Superior to International Counterparts
- Nov 18, 2023: Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023
- Nov 18, 2023: Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023
- Jun 08, 2023: Venus Medtech Hangzhou Notice of 2022 Annual General Meeting
- Mar 04, 2023: Confirmatory clinical trial of Liwen RF ablation system in China concluded
- Nov 25, 2022: Venus Medtech to showcase its structural heart treatments at London Valves 2022
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Venus Medtech Hangzhou Inc Pipeline Products and Ongoing Clinical Trials Overview
- Venus Medtech Hangzhou Inc Pipeline Products by Equipment Type
- Venus Medtech Hangzhou Inc Pipeline Products by Indication
- Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status
- Venus Medtech Hangzhou Inc, Key Facts
- Venus Medtech Hangzhou Inc, Major Products and Services
- Venus Medtech Hangzhou Inc Number of Pipeline Products by Development Stage
- Venus Medtech Hangzhou Inc Pipeline Products Summary by Development Stage
- Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status
- Venus Medtech Hangzhou Inc Ongoing Clinical Trials Summary
- AR Valve - Product Status
- AR Valve - Product Description
- Cardiovalve - Product Status
- Cardiovalve - Product Description
- Cardiovalve Transcatheter Tricuspid Valve System - Product Status
- Cardiovalve Transcatheter Tricuspid Valve System - Product Description
- Cardiovalve Transcatheter Tricuspid Valve System - Safety and Performance of the Cardiovalve TR Replacement System for Tricuspid Regurgitation
- Cardiovalve Transfemoral Mitral Valve System - Product Status
- Cardiovalve Transfemoral Mitral Valve System - Product Description
- Cardiovalve Transfemoral Mitral Valve System - Cardiovalve Transfemoral Mitral Valve System in Patients at High Surgical Risk with Severe Mitral Regurgitation
- Cardiovalve Transfemoral Mitral Valve System - European Feasibility Study of High Surgical Risk Patients with Severe Mitral Regurgitation Treated with the Cardiovalve Transfemoral Mitral Valve System: AHEAD Study
- Echomplish Device - Product Status
- Echomplish Device - Product Description
- Lim Transseptal System - Product Status
- Lim Transseptal System - Product Description
- Limbus - Product Status
- Limbus - Product Description
- Liwen RF Ablation System - Product Status
- Liwen RF Ablation System - Product Description
- Liwen RF Ablation System - Confirmatory Clinical Study of Liwen RF Ablation System
- Small Incision Surgical Valve - Product Status
- Small Incision Surgical Valve - Product Description
- Transapical Trinity Aortic Valve Implantation System - Product Status
- Transapical Trinity Aortic Valve Implantation System - Product Description
- Transcatheter Tricuspid Valve Replacement Device - Product Status
- Transcatheter Tricuspid Valve Replacement Device - Product Description
- Transfemoral Trinity Aortic Valve Implantation System - Product Status
- Transfemoral Trinity Aortic Valve Implantation System - Product Description
- Tresillo System - Product Status
- Tresillo System - Product Description
- TriGUARD3 Cerebral Embolic Protection Device - Product Status
- TriGUARD3 Cerebral Embolic Protection Device - Product Description
- Tumbao EndoVascular Aortic Repair System - Product Status
- Tumbao EndoVascular Aortic Repair System - Product Description
- Venus PowerX Valve - Product Status
- Venus PowerX Valve - Product Description
- Venus PowerX Valve - Pivotal Study of Severe Aortic Stenosis Treated with the Venus-PowerX Transcatheter Aortic Valve System
- Venus Vitae Valve - Product Status
- Venus Vitae Valve - Product Description
- Venus Vitae Valve - Multicenter Pivotal Study to Evaluate the Treatment of Severe Aortic Valve Stenosis With Next-Generation Venus-Vitae Transcatheter Heart Valve (THV) System
- Venus-Neo - Product Status
- Venus-Neo - Product Description
- Venus-Neo - A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve
- VenusP-Valve - Product Status
- VenusP-Valve - Product Description
- VenusP-Valve - A Real-World Evidence Observational Study of VenusP-ValveTM System in the Treatment of Patients with Native RVOT Dysfunction
- VenusP-Valve - Evaluation of the Performance of the VenusP-ValveTM System in Patients with Native RVOT Dysfunction
- VenusP-Valve - Implantation of the Venus P-Valve in the Pulmonic Position in Patients with Native Outflow Tracts
- Venus Medtech Hangzhou Inc, Key Employees
- Venus Medtech Hangzhou Inc, Subsidiaries
- Venus Medtech Hangzhou Inc, Joint Venture
- Glossary
- Venus Medtech Hangzhou Inc Pipeline Products by Equipment Type
- Venus Medtech Hangzhou Inc Pipeline Products by Development Stage
- Venus Medtech Hangzhou Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- LivaNova Japan KK
- Colibri Heart Valve LLC
- Edwards Lifesciences Corp
